BOLT Bolt Biotherapeutics, Inc.

NASDAQ
$3.35

Bolt Biotherapeutics, Inc. (BOLT) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $2.40 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.3% since its last earnings release on August 11, 2026.

Bolt Biotherapeutics Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($2.40)
Rev est $1.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.42

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

Sector

Healthcare

Industry

Biotechnology